Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Virus-based therapy takes on drug-resistant cancers in early trial

NCT ID NCT07190833

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 23 times

Summary

This early-phase study tests a new drug called OTS-412, made from a modified virus, alone or with other medicines (hydroxyurea and atezolizumab) in 27 adults with solid tumors that no longer respond to standard treatments. The main goal is to check safety and side effects, while also seeing if tumors shrink. This is not a cure, but aims to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TREATMENT-REFRACTORY SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dong-A University Hospital

    RECRUITING

    Busan, 49201, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Pusan National University Yangsan Hospital

    RECRUITING

    Busan, 50612, South Korea

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.